Seeking Alpha
Profile| Send Message|
( followers)  

In an attempt to find stocks that have recently used their respective 200-day Simple Moving Average (SMA) as support, and are now moving toward analysts' targets, I use a screen with the following parameters:

  • Average Analyst Recommendation = Buy or better
  • Price Below 50-day SImple Moving Average
  • Price Above 200-day SImple Moving Average
  • Current Price Under Average Analyst Price Target
  • Sorted by Price to Sales Ratio

From the results of the screen, 10 stocks, listed below, showed promise (sorted by upside potential, according to analysts' estimates):

AVEO Pharmaceuticals, Inc.
(AVEO) has grown from a $267.42 million market cap a year ago to a current market cap of $699.08 million. Analyst opinion for the company stands at five strong buys, one moderate buy, zero holds, zero moderate sells, and zero sells, with an average price target of $26.40, 62.76% above its current price level.

The stock is trading just under its 20-day and 50-day SMAs, -1.37% and -8.47%, respectively, but has resisted falling below its 200-day SMA and is now 1.22% above this average. As it seems to have used its 200-day SMA as support, AVEO Pharmaceuticals, Inc. could be making a turn toward analysts' estimates.




Rosetta Resources, Inc.
(ROSE) has yielded a 123.43% yearly return, a 22.87% Year to Date (YTD) return, and a 7.61% quarterly return. Analyst opinion for the company stands at ten strong buys, four moderate buys, seven holds, zero moderate sells, and zero sells, with an average price target of $63.53, 37.36% above its current price level.

The stock is trading 6.11% above its 20-day SMA and 4.08% below its 50-day SMA. Rosetta Resources, Inc. also looks to have found support at its 200-day SMA, currently 5.32% above the average, and could be making a move toward analysts' estimates.




Goldcorp Inc. (GG) has grown from a $32.51 billion market cap a year ago to a current market cap of $41.60 billion. Analyst opinion for the company stands at ten strong buys, five moderate buys, four holds, zero moderate sells, and one sell, with an average price target of $66.71, 29.56% above its current price level.

The stock is trading just under its 20-day and 50-day SMAs, -1.90% and -0.02%, respectively, but has resisted falling below its 200-day SMA and is now 6.82% above this support level. Goldcorp Inc. also looks to have established linear, up-trending support (shown below) and is on pace to continue its upward trend.




PDL BioPharma, Inc. (PDLI) has grown from a $678.53 million market cap a year ago to a current market cap of $805.19 million. Analyst opinion for the company stands at one strong buy, two moderate buys, three holds, zero moderate sells, and zero sells, with an average price target of $7.33, 27.26% above its current price level.

The stock is trading 0.92% above its 20-day SMA and 1.04% below its 50-day SMA. PDL BioPharma, Inc. also looks to have found support at its 200-day SMA, currently 2.87% above the average, and could be making a move toward analysts' estimates.




HollyFrontier Corp.
(HFC) has yielded a 149.18% yearly return, a 65.05% YTD return, and a 6.98% quarterly return. Analyst opinion for the company stands at seven strong buys, two moderate buys, six holds, zero moderate sells, and zero sells, with an average price target of $41.54, 24.41% above its current price level.

The stock is trading just under its 20-day and 50-day SMAs, -2.64% and -4.87%, respectively, but has resisted falling below its 200-day SMA and is now 15.60% above this support level. Though it hasn't traded near its 200-day SMA recently, HollyFrontier Corp. looks to be using linear, up-trending support (shown below) and, if it can stay above this support, should be reaching analysts' estimates in the not-so-distant future.




HealthSpring, Inc. (HS-OLD) has grown from a $1.20 billion market cap a year ago to a current market cap of $2.61 billion. Analyst opinion for the company stands at six strong buys, zero moderate buys, seven holds, zero moderate sells, and zero sells, with an average price target of $47.45, 23.50% above its current price level.

The stock is trading 3.47% above its 20-day SMA and 1.98% below its 50-day SMA. Though it fell sharply below its 200-day SMA in early August, HealthSpring, Inc. has climbed above this average and has since used this level as support for its recent-- and possibly continued-- climb.




Bridgepoint Education, Inc. (BPI) has grown from a $705.30 million market cap a year ago to a current market cap of $1.13 billion. Analyst opinion for the company stands at five strong buys, zero moderate buys, three holds, zero moderate sells, and zero sells, with an average price target of $26.30, 22.67% above its current price level.

The stock is trading 0.54% above its 20-day SMA and 9.12% below its 50-day SMA. Bridgepoint Education, Inc. looks to have found support at the $20.00 price level (shown below) as well as its 200-day SMA, currently 5.39% above the average.




CIGNA Corp. (CI) has yielded a 34.73% yearly return and a 26.67% YTD return but has stumbled recently, falling from its $52.00 July highs, yielding a -5.09% quarterly return. Analyst opinion for the company stands at nine strong buys, zero moderate buys, nine holds, one moderate sell, and zero sells, with an average price target of $55.29, 19.16% above its current price level.

The stock is trading 3.76% above its 20-day SMA and 0.96% below its 50-day SMA. Like HealthSpring, Inc., CIGNA Corp. also fell sharply through its 200-day SMA in early August but, now 4.32% above the average, is using this level as support and is currently heading toward analysts' price targets.




Unilever NV
(UN) has grown from a $75.41 billion market cap a year ago to a current market cap of $87.85 billion. Analyst opinion for the company stands at two strong buys, zero moderate buys, two holds, zero moderate sells, and zero sells, with an average price target of $36.33, 15.96% above its current price level.

The stock is trading just under its 20-day and 50-day SMAs, -4.50% and -3.36%, respectively, but has resisted falling below its 200-day SMA and is now 0.68% above this average. As it is currently just above linear, up-trending support (shown below) and its 200-day SMA support, Unilever NV could be making a move toward analysts' $36.33 price target.




Apollo Group, Inc. (APOL), though currently yielding a yearly return of -3.75%, has performed well recently with a 19.68% YTD return and a 13.41% quarterly return. Analyst opinion for the company stands at eight strong buys, one moderate buy, nine holds, zero moderate sells, and zero sells, with an average price target of $50.47, 6.79% above its current price level.

The stock is trading 3.40% above its 20-day SMA and 0.62% below its 50-day SMA. Now a substantial 9.86% above its 200-day SMA, Apollo Group, Inc. recently broke away from linear, up-trending support and looks to be continuing its movement upward. Though it is only 6.79% from analysts' targets, the stock recently reached the $54.00 price level, 14.26% above its current position, and could do so again in the coming months.




Data provided by SeekingAlpha.com, Yahoo! Finance, FinViz.com, Thomson Reuters, Zacks, and Kapitall.com.

Source: 10 Uptrending Stocks Heading Towards Analyst Estimates